1.10
price up icon0.00%   0.00
after-market Handel nachbörslich: 1.12 0.02 +1.82%
loading

Opko Health Inc Aktie (OPK) Neueste Nachrichten

pulisher
01:20 AM

OPKO Health (OPK) price target increased by 11.18% to 3.86 - MSN

01:20 AM
pulisher
May 14, 2026

OPKO Health stock (US68375N1037): Genomics leader with recent subsidiary activity - AD HOC NEWS

May 14, 2026
pulisher
May 12, 2026

ModeX to present preclinical CAR-T data at gene therapy meeting - Investing.com UK

May 12, 2026
pulisher
May 12, 2026

OPKO Health’s ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies - Yahoo Finance

May 12, 2026
pulisher
May 11, 2026

Spotlight On Promising Penny Stocks For May 2026 - simplywall.st

May 11, 2026
pulisher
May 08, 2026

OPK.O| Stock Price & Latest News - Reuters

May 08, 2026
pulisher
May 07, 2026

Here's why you should hold OPK stock in your portfolio for now - msn.com

May 07, 2026
pulisher
May 06, 2026

OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat

May 06, 2026
pulisher
May 05, 2026

MSN Money - MSN

May 05, 2026
pulisher
May 05, 2026

OPK Stock Price, Quote & Chart | OPKO HEALTH INC (NASDAQ:OPK) - ChartMill

May 05, 2026
pulisher
May 03, 2026

OPKO Health, Inc. (NASDAQ:OPK) Just Reported And Analysts Have Been Lifting Their Price Targets - 富途牛牛

May 03, 2026
pulisher
May 01, 2026

HC Wainwright Boosts Earnings Estimates for OPKO Health - MarketBeat

May 01, 2026
pulisher
May 01, 2026

OPKO Health : Notice Annual Meeting of stockholders be held on Thursday, June 18, 2026. - marketscreener.com

May 01, 2026
pulisher
Apr 30, 2026

OPKO gains 15% stake in Nicoya for China RAYALDEE rights - Investing.com UK

Apr 30, 2026
pulisher
Apr 30, 2026

[ARS] OPKO HEALTH, INC. SEC Filing - Stock Titan

Apr 30, 2026
pulisher
Apr 30, 2026

Board structure and pay detailed in OPKO Health (NASDAQ: OPK) 2026 proxy - Stock Titan

Apr 30, 2026
pulisher
Apr 30, 2026

OPKO gains 15% stake in Nicoya for China RAYALDEE rights By Investing.com - Investing.com South Africa

Apr 30, 2026
pulisher
Apr 30, 2026

OPKO Health receives 15% stake in Nicoya for China drug rights - StreetInsider

Apr 30, 2026
pulisher
Apr 30, 2026

OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China - marketscreener.com

Apr 30, 2026
pulisher
Apr 30, 2026

Q1 Earnings Estimate for OPKO Health Issued By HC Wainwright - MarketBeat

Apr 30, 2026
pulisher
Apr 30, 2026

Order lab tests online or at home: BioReference opens new platform - Stock Titan

Apr 30, 2026
pulisher
Apr 30, 2026

BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform - ChartMill

Apr 30, 2026
pulisher
Apr 29, 2026

OPKO Health (OPK) reports Q1 loss, misses revenue estimates - MSN

Apr 29, 2026
pulisher
Apr 29, 2026

OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y - sharewise.com

Apr 29, 2026
pulisher
Apr 29, 2026

OPKO Health Down Over 13%, On Pace for Largest Percent Decrease Since January 2024 -- Data Talk - Moomoo

Apr 29, 2026
pulisher
Apr 29, 2026

OPKO Health (NASDAQ:OPK) Hits New 1-Year LowShould You Sell? - MarketBeat

Apr 29, 2026
pulisher
Apr 29, 2026

This Purple Innovation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga

Apr 29, 2026
pulisher
Apr 29, 2026

H.C. Wainwright reiterates Opko Health stock rating on Q1 results By Investing.com - Investing.com Australia

Apr 29, 2026
pulisher
Apr 29, 2026

OPKO Health (NASDAQ:OPK) Downgraded to "Market Perform" Rating by Barrington Research - MarketBeat

Apr 29, 2026
pulisher
Apr 29, 2026

H.C. Wainwright reiterates Opko Health stock rating on Q1 results - Investing.com

Apr 29, 2026
pulisher
Apr 29, 2026

OPKO Health Q1 2026 Earnings Call: Complete Transcript - Benzinga

Apr 29, 2026
pulisher
Apr 29, 2026

OPKO Health Inc (OPK) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing ... By GuruFocus - Investing.com Canada

Apr 29, 2026
pulisher
Apr 29, 2026

Barrington Research downgrades OPKO Health (OPK) - MSN

Apr 29, 2026
pulisher
Apr 29, 2026

OPKO Health Q1 2026 Earnings Call Transcript - MarketBeat

Apr 29, 2026
pulisher
Apr 28, 2026

OPKO Health Q1 Earnings Call Highlights - MarketBeat

Apr 28, 2026
pulisher
Apr 28, 2026

OPK: Clinical pipeline advances and operational improvements drive improved Q1 2026 results - TradingView

Apr 28, 2026
pulisher
Apr 28, 2026

OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance

Apr 28, 2026
pulisher
Apr 28, 2026

OPKO Health (OPK) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance

Apr 28, 2026
pulisher
Apr 28, 2026

Earnings call transcript: OPKO Health Q1 2026 reveals revenue decline and stock dip By Investing.com - Investing.com South Africa

Apr 28, 2026
pulisher
Apr 28, 2026

Earnings call transcript: OPKO Health Q1 2026 reveals revenue decline and stock dip - Investing.com Nigeria

Apr 28, 2026
pulisher
Apr 28, 2026

Earnings Flash (OPK) OPKO Health Posts Q1 Loss of $0.07 per Share, vs. FactSet Est of $0.07 Loss - marketscreener.com

Apr 28, 2026
pulisher
Apr 28, 2026

OPKO Health Inc (NASDAQ:OPK) Misses Q1 Revenue Estimates, Shares Slide After Hours - ChartMill

Apr 28, 2026
pulisher
Apr 28, 2026

OPKO Health: Q1 Earnings Snapshot - Barchart.com

Apr 28, 2026
pulisher
Apr 28, 2026

OPKO Health (NASDAQ:OPK) Announces Quarterly Earnings Results, Hits Estimates - MarketBeat

Apr 28, 2026
pulisher
Apr 28, 2026

Earnings Flash (OPK) OPKO Health, Inc. Reports Q1 Revenue $124.2M, vs. FactSet Est of $130.5M - marketscreener.com

Apr 28, 2026
pulisher
Apr 28, 2026

OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results - The Manila Times

Apr 28, 2026
pulisher
Apr 28, 2026

(OPK) OPKO Health, Inc. Expects Q2 Revenue Range $127.0M$132.0M - marketscreener.com

Apr 28, 2026
DGX DGX
$186.61
price down icon 0.71%
MTD MTD
$1,031.64
price down icon 0.99%
$142.54
price down icon 0.49%
$186.36
price down icon 5.36%
IQV IQV
$169.12
price down icon 0.91%
A A
$111.70
price down icon 1.38%
Kapitalisierung:     |  Volumen (24h):